DOH Speaks on Efficacy Rate of Sinovac COVID-19 Vaccine
DOH – The Department of Health spoke on the Sinovac vaccine amid the spike in COVID-19 cases among vaccinated health workers in Indonesia.
Vaccinations against COVID-19 are currently ongoing in the different countries including the Philippines. Based on the vaccination ladder, the health workers are the top priority in the administration of the jabs. They are the frontliners in the fight against the spread of the disease.
Several brands of COVID-19 vaccines were developed. The list includes Sinovac, AstraZeneca, Sputnik V, Moderna, and Pfizer. Millions of jabs were procured by the the different countries in the pursuit for a herd immunity.
In the Philippines, China’s Sinovac is the brand of COVID-19 that is more in quantity compared other brands. However, the happenings in Indonesia caused alarm to some people.
More than 350 vaccinated doctors and health workers in Indonesia tested positive for COVID-19. Reports state that the vaccine given to them was China’s Sinovac.
Recently, the Department of Health (DOH) spoke on Sinovac amid the increasing COVID-19 cases of vaccinated health workers in Indonesia. Based on a report on ABS-CBN News, the Health Department stressed confidence in the efficacy rate of the vaccine developed by China.
According to DOH Undersecretary Maria Rosario Vergeire, there is a need to identify the percentage of the vaccinate workers who got COVID-19 in Indonesia to check on its efficacy rate in the country. She stressed that “breakthrough infections” is undeniable but there is a need for complete date to get a thorough analysis.
“Let’s get the vaccine. Let us not be doubtful. Let’s give that confidence kahit may lumalabas na ganitong mga balita,” Vergeire expressed.
With regards to the vaccinated health workers who got COVID-19 in Indonesia, most of them are asymptomatic while dozens are confined in hospitals. The latter exhibit high fever and dropping of oxygen levels.
Thank you for visiting Philnews.ph. You may express your thoughts and reactions below through the comment section. You may also follow us on Facebook, on Twitter, and subscribe to our YouTube channel Philnews Ph.